Following her appointment in 2009 as Operations Manager for Hungary, Dr Erika Nemeth has been promoted to Country Manager as Synexus increases capacity in its Hungarian operations.
Dr Christian Tueni, Synexus Regional Director for Central and Eastern Europe is delighted to start the New Year with this appointment: “Erika has already demonstrated her capabilities as Operations Manager and is ideally placed to lead our operations in Hungary in her new role. Following our acquisition of ClinPharm in December last year, we now have 16 dedicated research centres across the CEE region and Hungary is one of the most significant in terms of future growth potential. Erika will be working to extend the number of trials we run here and to support the business development team.”
Synexus is the world’s largest multi-national company entirely focused on the recruitment and running of clinical trials at its own dedicated research centres. The company’s recent acquisition of German-based ClinPharm has increased the number of dedicated research centres to 26 in nine countries. Synexus now has research centres in Western, Central and Eastern Europe, South Africa and Asia.
The ClinPharm acquisition has increased Synexus’ total patient population reach to over 30 million; an increase of 50 per cent globally and 100 per cent across Europe. No other patient recruitment organisation can compete in terms of size or scale. ClinPharm also brings considerable additional therapy area experience to Synexus.
Synexus® headquartered in Manchester, England, is the world’s largest multi-national company dedicated to the recruitment and running of clinical trials at its own research centres across the globe on behalf of its pharmaceutical, biotech and CRO clients. Synexus now has 26 Dedicated Research Centres across the UK, Germany, Austria, Poland, Hungary, Ukraine, Bulgaria, India and South Africa staffed by full-time GCP-trained investigators.
The traditional way of recruiting for clinical trials through individual doctors is still by far the most common method, despite the fact that each doctor only recruits an average of five patients per study and more than 40 percent recruit one or less. This incredibly costly model remains the norm.
